|
|
| (47 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 4: |
Zeile 4: |
| | | | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| | + | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − |
| |
| − |
| |
| | *'''[[Clinical guidelines and advice]]''' | | *'''[[Clinical guidelines and advice]]''' |
| − | {{tp|p=32359076|t=2020. COVID-19: Use of the Clinical Frailty Scale for Critical Care Decisions |pdf=|usr=}}
| |
| − | {{tp|p=32215647|t=2020. Management of Critically Ill Adults With COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32159735|t=2020. Care for Critically Ill Patients With COVID-19 |pdf=|usr=}}
| |
| | | | |
| | | | |
| − |
| |
| − | {{tp|p=32369222|t=2020. The management of coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| |
| | | | |
| | *'''[[Respiration mgmt]]''' | | *'''[[Respiration mgmt]]''' |
| − | {{tp|p=32249028|t=2020. The "helmet bundle" in COVID-19 patients undergoing non invasive ventilation |pdf=|usr=}}
| |
| − | {{tp|p=32268933|t=2020. Home PAP devices in COVID-19 infected patients |pdf=|usr=}}
| |
| − | {{tp|p=32074258|t=2020. Preparing for the Most Critically Ill Patients With COVID-19: The Potential Role of Extracorporeal Membrane Oxygenation |pdf=|usr=}}
| |
| − | {{tp|p=32329799|t=2020. Management of COVID-19 Respiratory Distress |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Diagnosis (Laboratory)]]''' |
| | | | |
| − |
| |
| − |
| |
| − | *'''[[Diagnosis (Laboratory)]]'''
| |
| | | | |
| | *'''[[Diagnosis (Lung CT, Sonography)]]''' | | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| − |
| |
| | | | |
| | *'''[[Diagnosis (other modalities)]]''' | | *'''[[Diagnosis (other modalities)]]''' |
| | | | |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| − | {{tp|p=32238585|t=2020. Isolation and Full-Length Genome Characterization of SARS-CoV-2 from COVID-19 Cases in Northern Italy |pdf=|usr=}}
| + | |
| − | {{tp|p=32238584|t=2020. Computational inference of selection underlying the evolution of the novel coronavirus, SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32365353|t=2020. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Target binding and uptake]]''' | | *'''[[Target binding and uptake]]''' |
| − | {{tp|p=32225176|t=2020. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor |pdf=|usr=}}
| |
| − | {{tp|p=32225175|t=2020. Structural basis of receptor recognition by SARS-CoV-2 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| − |
| |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| | | | |
| Zeile 57: |
Zeile 34: |
| | | | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{tp|p=32376901|t=ä. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages |pdf=|usr=}}
| |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| − | {{tp|p=32343429|t=2020. Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis |pdf=|usr=}}
| |
| − | {{tp|p=32192578|t=2020. COVID-19: consider cytokine storm syndromes and immunosuppression |pdf=|usr=}}
| |
| | | | |
| − | ----
| + | |
| | + | |
| | *'''[[Pathobiology]]''' | | *'''[[Pathobiology]]''' |
| | + | |
| | | | |
| | *'''[[Disease Models]]''' | | *'''[[Disease Models]]''' |
| − | {{tp|p=32380511|t=2020. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Similar diseases and pathomechanisms]]''' | | *'''[[Similar diseases and pathomechanisms]]''' |
| − | {{tp|p=32319148|t=2020. COVID-19: searching for clues among other respiratory viruses |pdf=|usr=}}
| |
| − | {{tp|p=32237148|t=2020. Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: a retrospective study from a single center |pdf=|usr=}}
| |
| − | {{tp|p=32265517|t=2020. SARS-CoV-2 detection in patients with influenza-like illness |pdf=|usr=}}
| |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| Zeile 82: |
Zeile 53: |
| | | | |
| | *'''[[Systemic disease, any manifestations]]''' | | *'''[[Systemic disease, any manifestations]]''' |
| | + | |
| | *'''[[Co-Infection]]''' | | *'''[[Co-Infection]]''' |
| − | {{tp|p=32339350|t=2020. COVID-19 associated pulmonary aspergillosis |pdf=|usr=}}
| |
| | | | |
| − |
| |
| − | *'''[[ARDS]]'''
| |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| | + | |
| | + | |
| | | | |
| | | | |
| | | | |
| | *'''[[Hematology]]''' | | *'''[[Hematology]]''' |
| | + | |
| | | | |
| | | | |
| Zeile 109: |
Zeile 81: |
| | *'''[[Gastroenterology, hepatology]]''' | | *'''[[Gastroenterology, hepatology]]''' |
| | | | |
| | + | *'''[[Kidney, urology]]''' |
| | | | |
| | + | *'''[[The morbid survivor]]''' |
| | | | |
| | + | *'''[[Risk and special populations]]''' |
| | | | |
| | | | |
| | | | |
| | + | *'''[[Case reports]]''' |
| | | | |
| | | | |
| Zeile 120: |
Zeile 96: |
| | | | |
| | | | |
| − | *'''[[Kidney, urology]]'''
| |
| − | {{tp|p=32249664|t=2020. Focus on the Crosstalk Between COVID-19 and Urogenital Systems |pdf=|usr=}}
| |
| − | {{tp|p=32365180|t=ä. Potential influence of COVID-19/ACE2 on the female reproductive system |pdf=|usr=}}
| |
| | | | |
| − |
| |
| − |
| |
| − |
| |
| − | *'''[[Risk and special populations]]'''
| |
| − |
| |
| − |
| |
| − |
| |
| − | *'''[[The morbid survivor]]'''
| |
| − | *'''[[Case reports]]'''
| |
| | *'''[[Case series]]''' | | *'''[[Case series]]''' |
| | | | |
| | | | |
| | *'''[[Registries]]''' | | *'''[[Registries]]''' |
| − | {{tp|p=32377641|t=ä. Initial data from the COVID-19 Global Rheumatology Alliance provider registries |pdf=|usr=}}
| |
| − | {{tp|p=32377642|t=ä. Initial data from the COVID-19 Global Rheumatology Alliance provider registries ? Authors reply |pdf=|usr=}}
| |
| − |
| |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| − | {{tp|p=32379296|t=2020. Inclusion of Children in Clinical Trials of Treatments for Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32341581|t=2020. Antibody testing will enhance the power and accuracy of COVID-19-prevention trials |pdf=|usr=}}
| |
| − | {{tp|p=32179860|t=2020. Don t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees |pdf=|usr=}}
| |
| | | | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| | + | |
| | | | |
| | *'''[[Other routes of infection]]''' | | *'''[[Other routes of infection]]''' |
| − | {{tp|p=32367576|t=2020. Saliva is a non-negligible factor in the spread of COVID-19 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Biophysics of aerosols]]''' | | *'''[[Biophysics of aerosols]]''' |
| − | {{tp|p=32215590|t=2020. Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32340022|t=2020. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32320083|t=2020. Decontamination of face masks with steam for mask reuse in fighting the pandemic COVID-19: experimental supports |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| Zeile 166: |
Zeile 124: |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| − | {{tp|p=32314806|t=2020. Psychological stress of medical staffs during outbreak of COVID-19 and adjustment strategy |pdf=|usr=}}
| |
| | | | |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| | + | |
| | + | |
| | | | |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| − | {{tp|p=32359403|t=ä. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands |pdf=|usr=}}
| + | |
| − | {{tp|p=32343497|t=ä. Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| | + | |
| | + | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| − | {{tp|p=32377508|t=ä. Review on government action plans to reduce energy consumption in buildings amid COVID-19 pandemic outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32273610|t=2020. If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future |pdf=|usr=}}
| |
| − | {{tp|p=32269308|t=2020. COVID-19 brings drug development to a halt |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 188: |
Zeile 145: |
| | | | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| | + | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| | + | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| | + | |
| | + | |
| | + | |
| | | | |
| | | | |
| | *'''[[Remission, recurrence and persistence]]''' | | *'''[[Remission, recurrence and persistence]]''' |
| − | {{tp|p=32296168|t=2020. Temporal dynamics in viral shedding and transmissibility of COVID-19 |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Failure of executive measures]]''' | | *'''[[Failure of executive measures]]''' |
| | ---- | | ---- |
| | *'''[[Failure of politics and public health guidance]]''' | | *'''[[Failure of politics and public health guidance]]''' |
| − | {{tp|p=32352911|t=2020. COVID-19 reveals weak health systems by design: Why we must re-make global health in this historic moment |pdf=|usr=}}
| + | |
| − | {{tp|p=32273583|t=2020. When COVID-19 meets centralized, personalized power |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − | {{tp|p=32371962|t=2020. Going viral: how to boost the spread of coronavirus science on social media |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Lost people]]''' | | *'''[[Lost people]]''' |
| − | {{tp|p=32317499|t=2020. A tribute to frontline corona warriors--Doctors who sacrificed their life while saving patients during the ongoing COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32238428|t=2020. Dr Li Wenliang and the Time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32303602|t=2020. Letter to the Editor: Who was the first doctor to report the Covid-19 outbreak in Wuhan, China?|pdf=|usr=}}
| |
| − | {{tp|p=32310289|t=2020. Health Care Heroes of the COVID-19 Pandemic |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| − | {{tp|p=32374357|t=2020. The Ethics of COVID-19 Immunity-Based Licenses ("Immunity Passports") |pdf=|usr=}}
| |
| − | {{tp|p=32380041|t=2020. COVID-19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | ---- | | ---- |
| Zeile 224: |
Zeile 175: |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| | + | *'''[[misc.]]''' |
| | | | |
| | | | |
| | + | *'''[[Research tools]]''' |
| | | | |
| − | *'''[[misc.]]'''
| |
| | | | |
| − | *'''[[Research tools]]'''
| |
| − | {{tp|p=32339250|t=2020. A potential ex vivo infection model of human induced pluripotent stem cell-3D organoids beyond coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32275081|t=2020. Evaluate severe acute respiratory syndrome coronavirus 2 infectivity by pseudoviral particles |pdf=|usr=}}
| |
| − | {{tp|p=32365353|t=2020. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform |pdf=|usr=}}
| |
| − | {{tp|p=32349121|t=2020. Massively multiplexed nucleic acid detection with Cas13 |pdf=|usr=}}
| |
| | | | |
| | + | |
| | + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | | | |
| | | | |
| | *'''[[PrePrint scene]]''' | | *'''[[PrePrint scene]]''' |
| | + | |
| | + | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| | + | |
| | *'''[[Current state of coviki.org]]''' | | *'''[[Current state of coviki.org]]''' |
| | *'''[[on-topic personal thoughts]]''' | | *'''[[on-topic personal thoughts]]''' |
